Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: sargramostim, mavrilimumab | 0.81 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 2 Parkinson's papers of 130 | 0.85 |
| pathways Reactome | 6 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 5117
Sealed predictions
- CSF2RA in dopamine neurons, braak-0.44 (p 0.232) → -0.73 (p 0.025)receipt 5125
Swarm cases
receipt 5125: CSF2RA in dopamine neurons, braak
- power
- full sample -0.58 (p 0.011, n 18), 95% CI -0.82 to -0.16. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.57 (p 0.013, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.60 (p 0.0080, n 18). not the mix.
- skeptic
- leave-one-out range -0.65 to -0.52, sign flips 0; without severely affected donors -0.58 (p 0.011, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CSF2RA in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts